RCE Recce Pharmaceuticals

Recce Pharmaceuticals Appoints Synthetic Anti-infectives Expert Michele Dilizia as Chief Scientific Officer

Recce Pharmaceuticals Appoints Synthetic Anti-infectives Expert Michele Dilizia as Chief Scientific Officer
EN
14/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Recce Pharmaceuticals

 PRESS RELEASE

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial ...

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocolProgram enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)Access focused on patients with DFU infections given the unmet medical need...

 PRESS RELEASE

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$1...

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer price as the placementFunds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026Directors intend to take up entitlements in part or in full in the Entitlement Offer SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a ...

 PRESS RELEASE

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectiv...

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041. “We are encouraged by the Japan Patent Office’s formal recognition of Recce’s new class of anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Global patent protection underscores our c...

 PRESS RELEASE

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of REC...

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway Phase II trial assessed the efficacy and safety of RECCE® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections (DFI)Study objectives exceeded, with a 93% primary efficacy endpoint achieved for R327G over 14 days of treatmentData confirms the approach for the approved registrational Phase 3 DFI study in Indonesia, where eff...

 PRESS RELEASE

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 3...

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional Australian regulatory trials to be initiated in H1 2025 SYDNEY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced the d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch